Mandate

Vinge advises EQT VI on acquisition of Atos Medical

July 22, 2011

Vinge is advising funds managed by EQT VI Limited in connection with the acquisition of Atos Medical from funds managed by Nordic Capital V Limited (94.6%) and board directors and employees (5.4%). Atos supplies products to the ear, nose and throat (“ENT”) medical segment and is the market leader in voice prosthesis. The acquisition is subject to customary conditions.

The Vinge team included partners Christina Kokko and Johan Göthberg and associates Malin Helgesen, Peter Sundgren, Paul Dali and Anna-Sofia Nilsson Prevell (M&A), partner Maria-Pia Hope and associates Albert Wållgren and Andreas Malmberg (banking & finance), and partner Marcus Glader and associate Peter Alstergren (EU & competition).

Related

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026

Vinge advises InArea on entering into a SEK 450 million credit agreement with SEB

InArea's new facilities agreement comprises a term loan and a revolving credit facility, replacing the company's existing facilities. The facilities agreement also includes an option to increase the lending framework through an incremental facility of up to SEK 200 million.
June 03, 2026

Vinge has advised the arrangers in connection with St1 Biokraft’s EUR 260 million financing

Vinge has advised the arrangers, ING Bank N.V., ABN AMRO Bank N.V., DNB Bank ASA, Nordea Bank Abp, OP Corporate Bank plc, Coöperatieve Rabobank U.A., SpareBank 1 Sør-Norge ASA and Swedbank AB, in connection with St1 Biokraft AB’s EUR 260 million financing.
June 03, 2026